Oxaliplatin upregulates Cyr61 expression by inhibiting the Hippo-YAP pathway which contributes to drug resistance of colorectal cancer cells.
[BACKGROUND] Oxaliplatin (OXA) resistance poses a significant challenge to the efficacy of chemotherapy for advanced colorectal cancer (CRC).
APA
Lu P, Zheng C, et al. (2026). Oxaliplatin upregulates Cyr61 expression by inhibiting the Hippo-YAP pathway which contributes to drug resistance of colorectal cancer cells.. Discover oncology, 17(1). https://doi.org/10.1007/s12672-026-04530-2
MLA
Lu P, et al.. "Oxaliplatin upregulates Cyr61 expression by inhibiting the Hippo-YAP pathway which contributes to drug resistance of colorectal cancer cells.." Discover oncology, vol. 17, no. 1, 2026.
PMID
41606217
Abstract
[BACKGROUND] Oxaliplatin (OXA) resistance poses a significant challenge to the efficacy of chemotherapy for advanced colorectal cancer (CRC). This study aimed to elucidate the role of OXA in regulating Cysteine-rich protein 61 (Cyr61) expression via the Hippo-Yes-associated protein (YAP) pathway in the context of chemotherapy-induced drug resistance.
[METHODS] We used Cell Counting Kit-8 to detect cell viability and proliferation. Expression of Cyr61 was determined by quantitative real-time PCR, western blotting (WB) and Enzyme-linked immunosorbent assay in CRC cell lines. The mechanism of OXA in regulating Cyr61 expression was studied by WB and co-immunoprecipitation.
[RESULTS] The results revealed that exposure to varying concentrations of OXA for 24 h induced increased mRNA and protein levels of Cyr61 in HCT8 and HCT116 CRC cells. Mechanistically, OXA-mediated overexpression of Cyr61 in CRC cells was attributed to inhibition of the Hippo-YAP pathway.
[CONCLUSIONS] These findings provide novel insights into the mechanisms underlying chemotherapy-induced drug resistance in CRC and highlight the release of Cyr61 by CRC cells as a potential therapeutic target for overcoming OXA resistance in CRC.
[METHODS] We used Cell Counting Kit-8 to detect cell viability and proliferation. Expression of Cyr61 was determined by quantitative real-time PCR, western blotting (WB) and Enzyme-linked immunosorbent assay in CRC cell lines. The mechanism of OXA in regulating Cyr61 expression was studied by WB and co-immunoprecipitation.
[RESULTS] The results revealed that exposure to varying concentrations of OXA for 24 h induced increased mRNA and protein levels of Cyr61 in HCT8 and HCT116 CRC cells. Mechanistically, OXA-mediated overexpression of Cyr61 in CRC cells was attributed to inhibition of the Hippo-YAP pathway.
[CONCLUSIONS] These findings provide novel insights into the mechanisms underlying chemotherapy-induced drug resistance in CRC and highlight the release of Cyr61 by CRC cells as a potential therapeutic target for overcoming OXA resistance in CRC.
같은 제1저자의 인용 많은 논문 (5)
- Multidimensional single-cell analysis of the molecular characteristics and functional pathways of Regulatory T cells in the microenvironment of HR+ breast cancer.
- Unveiling GULP1 as a hepatocyte-specific role for recurrence: Editorial on "GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma".
- Lipid metabolism in colorectal cancer: dual roles and statin therapy.
- Prediction of circRNA-Disease Associations Based on Graph Isomorphism Networks and Graph Sampling Aggregation.
- SOHO State of the Art Updates and Next Questions | CD7 CAR-T Therapy for Treating CD7-Positive Hematological Malignancies: Clinical Advances and Future Directions.